Brief: Atea Pharmaceuticals Presents Favorable At-752 Phase 1 Data For Treatment Of Dengue Fever At American Society Of Tropical Medicine & Hygiene 2022 Annual Meeting
03/11/2022 11:46
Nov 3 (Reuters) - Atea Pharmaceuticals Inc AVIR.O :
* ATEA PHARMACEUTICALS PRESENTS FAVORABLE AT-752 PHASE 1
DATA FOR
TREATMENT OF DENGUE FEVER AT AMERICAN SOCIETY OF TROPICAL
MEDICINE & HYGIENE 2022 ANNUAL MEETING
Source text for Eikon: ID:nGNX2WwCJ1
Further company coverage: AVIR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Atea Pharmaceuticals
See all newsAtea Pharmaceuticals Q2 loss narrows as HCV trial expenses decline
Atea Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Atea Pharmaceuticals, Inc. expected to post a loss of 56 cents a share - Earnings Preview
Atea Pharmaceuticals, Inc. expected to post a loss of 56 cents a share - Earnings Preview
NASDAQ RESUMED AT 07:30 AM